Chemed Corp. (CHE) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Chemed Corp. · Health Care · ref. ETF XLV · 51 calls · price $500.77
What the company does: Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States.
📈 Chemed Corp. (CHE) stock price
$500.77+14.6% over range
Oct 14, 25low $368.59 · high $552.72Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
50% recommend buying · 4 analysts
📊 JPI status : Chemed Corp. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 CHE price target & analyst consensus — price $501
The price target · all analysts combined (4 targets)
Highest target · 1 firm of 4$650+29.8%
Median target · of 4 targets$569+13.6%
Lowest target · 1 firm of 4$510+1.8%
Current price$500.77
Where these 4 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
4100%
$510 ↔ $650
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Oppenheimer — 69% of its targets hit on this sector (70 calls tested). It aims for $590 (+18 %), call made on August 1, 2026, maturing on August 1, 2027 (74 d ago).
The 3 reliable analysts
$590+18 %
The 1 other firm
$510+1.8 %
How to read it: the 3 reliable firms are not filtered by optimism — 3 aim above the price, 0 below, hence their $590 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 4 ratings (last 6 months)
Strong Buy00%
Buy250%
Hold250%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 CHE price target all
All 51 calls, one by one, with our verdict on each firm.
→ See all 51 targets, analyst by analyst💡 The best analysts on CHE most reliable
Their real reliability on CHE, firm by firm: who was right, who was wrong.
→ See their reliability on CHEAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Chemed Corp.? The JPI assistant answers using our backtest data.
💰 Chemed Corp. dividend: yield, history & growth › open the full page
0.50%annual yield
📈 Steady dividend — 17 yrs of consecutive dividend increases
That's ~$2.40 per share per year.
📈 Chemed Corp. fundamentals: valuation, margins & growth › open the full page
P/E 25.2Net margin 10.6 %Revenue growth +8.8 %Cheap for the growth
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. 12 %
2023
Rev +6%Profit +9%
2024
Rev +7%Profit +11%
2025
Rev +4%Profit −12%
🔎 Detailed analyses
🏛️ Which US Congress members hold Chemed Corp. (CHE)?
1 Congress member has disclosed CHE buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Lisa McClain 1×
✅ Historical analyst reliability on CHE
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Oppenheimer ↗ | 75% | +8.4% | 12 |
| B of A Securities ↗ | 67% | +14.8% | 3 |
| RBC Capital ↗ | 59% | +0.8% | 17 |
📊 What $1,000 invested in Chemed Corp. would be worth › open the full page
In short — $1,000 invested in Chemed Corp. 10 years ago would be worth $3,319 today, i.e. +13%/yr on average. Best year: 2017 (+57%), worst: 2025 (-24%). Price performance, excluding dividends.
If I'd invested $1,000 in Chemed Corp.
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $829 | -17% |
| 3 years ago | $922 | -8% |
| 5 years ago | $899 | -10% |
Return by year (Chemed Corp.)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +9% | $1,090 (+9%) |
| 2025 | -24% | $829 (-17%) |
| 2024 | -5% | $786 (-21%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Chemed Corp.
Loading news…
📋 All analyst calls on CHE
Filtered on — · ✕ show all
▲ Buy · 🎯$650
Price at call : $514.3 — upside +26%
Today : $500.77 — upside +30%
🎯 on CHE : no call matured yet · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Sep 25, 27
matures : Sep 25, 27
Oppenheimer ↗
Jul 31, 26
▲ Outperform · 🎯$590
Price at call : $540.57 — upside +9%
Today : $500.77 — upside +18%
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
in progress (365j)
matures : Jul 31, 27
matures : Jul 31, 27
RBC Capital ↗
Jul 30, 26
■ Sector Perform neutral · not a buy · 🎯$548
Price at call : $532.25 — gap to target +3%
Today : $500.77 — gap to target +9%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Jul 30, 27
matures : Jul 30, 27
B of A Securities ↗
Jul 9, 26
■ Neutral neutral · not a buy · 🎯$510
Price at call : $490.46 — gap to target +4%
Today : $500.77 — gap to target +2%
🎯 on CHE : 67% (3 calls matureds) · 📊 on Health : 64.2% · +20.2% (109 calls)
in progress (365j)
matures : Jul 9, 27
matures : Jul 9, 27
RBC Capital ↗
Apr 27, 26
■ Sector Perform neutral · not a buy · 🎯$436
Price at call : $421.1 — gap to target +4%
Today : $500.77 — gap to target -13%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Apr 27, 27
matures : Apr 27, 27
RBC Capital ↗
Feb 27, 26
■ Sector Perform neutral · not a buy · 🎯$422
Price at call : $421.4 — gap to target +0%
Today : $500.77 — gap to target -16%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Feb 27, 27
matures : Feb 27, 27
Oppenheimer ↗
Feb 27, 26
▲ Outperform · 🎯$500
Price at call : $421.4 — upside +19%
Today : $500.77 — upside -0%
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
in progress (365j)
matures : Feb 27, 27
matures : Feb 27, 27
■ Hold neutral · not a buy · 🎯$475
Price at call : $444.74 — gap to target +7%
Today : $500.77 — gap to target -5%
🎯 on CHE : 100% (1 call matured) · 📊 on Health : 48.3% · +10.7% (116 calls)
in progress (365j)
matures : Jan 22, 27
matures : Jan 22, 27
See the other 43 calls, newest to oldest
RBC Capital ↗
Nov 10, 25
▲ Outperform · 🎯$572
Price at call : $445.53 — upside +28%
Today : $500.77 — upside +14%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Nov 10, 26
matures : Nov 10, 26
B of A Securities ↗
Sep 10, 25
▲ Buy · 🎯$595
Price at call : $457.89 — upside +30%
Today : $500.77 — upside +19%
Expected +30% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 67% (3 calls matureds) · 📊 on Health : 64.2% · +20.2% (109 calls)
+12.7%
stock +13% · XLV +18%
matured Sep 10, 26
▲ Buy · 🎯$550
Price at call : $464 — upside +19%
Today : $500.77 — upside +10%
Expected +19% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 100% (1 call matured) · 📊 on Health : 48.3% · +10.7% (116 calls)
+12.9%
stock +13% · XLV +26%
matured Sep 2, 26
RBC Capital ↗
Jul 31, 25
▲ Outperform · 🎯$589
Price at call : $417.85 — upside +41%
Today : $500.77 — upside +18%
Expected +41% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+29.4%
stock +29% · XLV +24%
matured Jul 31, 26
Oppenheimer ↗
Jul 31, 25
▲ Outperform · 🎯$580
Price at call : $412.3 — upside +41%
Today : $500.77 — upside +16%
Expected +41% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+29.1%
stock +29% · XLV +25%
matured Jul 31, 26
■ Hold neutral · not a buy · 🎯$500
Price at call : $470.72 — gap to target +6%
Today : $500.77 — gap to target -0%
🎯 on CHE : 100% (1 call matured) · 📊 on Health : 48.3% · +10.7% (116 calls)
in progress (365j)
matures : Jul 25, 26
matures : Jul 25, 26
RBC Capital ↗
Jun 30, 25
▲ Outperform · 🎯$640
Price at call : $483.92 — upside +32%
Today : $500.77 — upside +28%
Expected +32% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-0.6%
stock -1% · XLV +17%
matured Jun 30, 26
B of A Securities ↗
Jun 30, 25
▲ Buy · 🎯$650
Price at call : $486.93 — upside +33%
Today : $500.77 — upside +30%
Expected +33% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 67% (3 calls matureds) · 📊 on Health : 64.2% · +20.2% (109 calls)
-4.3%
stock -4% · XLV +18%
matured Jun 30, 26
RBC Capital ↗
Apr 28, 25
▲ Outperform · 🎯$674
Price at call : $574.96 — upside +17%
Today : $500.77 — upside +35%
Expected +17% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-26.3%
stock -26% · XLV +3%
matured Apr 28, 26
RBC Capital ↗
Mar 14, 25
▲ Outperform · 🎯$667
Price at call : $608.07 — upside +10%
Today : $500.77 — upside +33%
Expected +10% · Actual -34% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-34.5%
stock -34% · XLV +3%
matured Mar 14, 26
RBC Capital ↗
Nov 5, 24
▲ Outperform · 🎯$633
Price at call : $549.99 — upside +15%
Today : $500.77 — upside +26%
Expected +15% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-21.7%
stock -22% · XLV -1%
matured Nov 5, 25
RBC Capital ↗
May 21, 24
▲ Outperform · 🎯$697
Price at call : $558.12 — upside +25%
Today : $500.77 — upside +39%
Expected +25% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+0.6%
stock +1% · XLV -11%
matured May 21, 25
RBC Capital ↗
Mar 4, 24
▲ Outperform · 🎯$712
Price at call : $636.72 — upside +12%
Today : $500.77 — upside +42%
Expected +12% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-6.5%
stock -7% · XLV +3%
matured Mar 4, 25
Oppenheimer ↗
Feb 29, 24
▲ Outperform · 🎯$650
Price at call : $613.81 — upside +6%
Today : $500.77 — upside +30%
Expected +6% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-3.7%
stock -4% · XLV +2%
matured Feb 28, 25
Oppenheimer ↗
Jan 17, 24
▲ Outperform · 🎯$625
Price at call : $593.06 — upside +5%
Today : $500.77 — upside +25%
Expected +5% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-6.5%
stock -6% · XLV +1%
matured Jan 16, 25
RBC Capital ↗
Oct 30, 23
▲ Outperform · 🎯$604
Price at call : $562.65 — upside +7%
Today : $500.77 — upside +21%
Expected +7% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-4.8%
stock -5% · XLV +19%
matured Oct 29, 24
RBC Capital ↗
Jul 31, 23
▲ Outperform · 🎯$576
Price at call : $520.99 — upside +11%
Today : $500.77 — upside +15%
Expected +11% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+9.4%
stock +9% · XLV +12%
matured Jul 30, 24
Oppenheimer ↗
Jul 27, 23
▲ Outperform · 🎯$590
Price at call : $523.21 — upside +13%
Today : $500.77 — upside +18%
Expected +13% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+6.0%
stock +6% · XLV +11%
matured Jul 26, 24
RBC Capital ↗
May 1, 23
▲ Outperform · 🎯$610
Price at call : $552.96 — upside +10%
Today : $500.77 — upside +22%
Expected +10% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+2.7%
stock +3% · XLV +5%
matured Apr 30, 24
Oppenheimer ↗
Apr 28, 23
▲ Outperform · 🎯$610
Price at call : $552.96 — upside +10%
Today : $500.77 — upside +22%
Expected +10% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+2.5%
stock +2% · XLV +5%
matured Apr 27, 24
RBC Capital ↗
Feb 27, 23
▲ Outperform · 🎯$587
Price at call : $535.55 — upside +10%
Today : $500.77 — upside +17%
Expected +10% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+11.4%
stock +11% · XLV +15%
matured Feb 27, 24
RBC Capital ↗
Nov 3, 22
▲ Outperform · 🎯$545
Price at call : $481.1 — upside +13%
Today : $500.77 — upside +9%
Expected +13% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+21.1%
stock +21% · XLV -2%
matured Nov 3, 23
RBC Capital ↗
Aug 1, 22
▲ Outperform · 🎯$541
Price at call : $470.28 — upside +15%
Today : $500.77 — upside +8%
Expected +15% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+10.8%
stock +11% · XLV +2%
matured Aug 1, 23
RBC Capital ↗
Apr 28, 22
▲ Outperform · 🎯$592
Price at call : $499.51 — upside +19%
Today : $500.77 — upside +18%
Expected +19% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+10.4%
stock +10% · XLV -0%
matured Apr 28, 23
RBC Capital ↗
Mar 4, 22
▲ Outperform · 🎯$579
Price at call : $485.9 — upside +19%
Today : $500.77 — upside +16%
Expected +19% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+6.2%
stock +6% · XLV -3%
matured Mar 4, 23
RBC Capital ↗
Jul 29, 21
▲ Outperform · 🎯$609
Price at call : $476.02 — upside +28%
Today : $500.77 — upside +22%
Expected +28% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-1.2%
stock -1% · XLV -1%
matured Jul 29, 22
Oppenheimer ↗
Feb 25, 21
▲ Outperform · 🎯$580
Price at call : $445.21 — upside +30%
Today : $500.77 — upside +16%
Expected +30% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+7.4%
stock +7% · XLV +15%
matured Feb 25, 22
RBC Capital ↗
Mar 11, 20
▲ Outperform · 🎯$535
Price at call : $414.05 — upside +29%
Today : $500.77 — upside +7%
Expected +29% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+7.0%
stock +7% · XLV +25%
matured Mar 11, 21
Oppenheimer ↗
Feb 19, 20
▲ Outperform · 🎯$535
Price at call : $487.26 — upside +10%
Today : $500.77 — upside +7%
Expected +10% · Actual -0% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-0.2%
stock -0% · XLV +11%
matured Feb 18, 21
Oppenheimer ↗
Nov 25, 19
■ Perform neutral · not a buy · 🎯$470
Price at call : $427.75 — gap to target +10%
Today : $500.77 — gap to target -6%
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
in progress (365j)
matures : Nov 24, 20
matures : Nov 24, 20
JMP Securities
Nov 1, 19
▲ Market Outperform · 🎯$490
Price at call : $411.17 — upside +19%
Today : $500.77 — upside -2%
Expected +19% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 100% (1 call matured) · 📊 unranked overall
+17.1%
stock +17% · XLV +9%
matured Oct 31, 20
RBC Capital ↗
Feb 25, 19
■ Sector Perform neutral · not a buy · 🎯$318
Price at call : $326.45 — gap to target -3%
Today : $500.77 — gap to target -36%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Feb 25, 20
matures : Feb 25, 20
B of A Securities ↗
Oct 12, 18
▲ Buy · 🎯$390
Price at call : $303.24 — upside +29%
Today : $500.77 — upside -22%
Expected +29% · Actual +36% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 67% (3 calls matureds) · 📊 on Health : 64.2% · +20.2% (109 calls)
+35.9%
stock +36% · XLV -1%
matured Oct 12, 19
Oppenheimer ↗
Oct 27, 17
▲ Outperform · 🎯$225
Price at call : $222.65 — upside +1%
Today : $500.77 — upside -55%
Expected +1% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+25.2%
stock +25% · XLV +8%
matured Oct 27, 18
■ Sector Weight neutral · not a buy
🎯 on CHE : no call matured yet · 📊 on Health : 31.9% · -11.8% (47 calls)
in progress (365j)
matures : Aug 28, 18
matures : Aug 28, 18
Oppenheimer ↗
Sep 22, 15
▲ Outperform · 🎯$150
Price at call : $138.13 — upside +9%
Today : $500.77 — upside -70%
Expected +9% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+1.2%
stock +1% · XLV +5%
matured Sep 21, 16
Oppenheimer ↗
Apr 29, 15
▲ Outperform · 🎯$130
Price at call : $117.82 — upside +10%
Today : $500.77 — upside -74%
Expected +10% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+11.8%
stock +12% · XLV -3%
matured Apr 28, 16
Deutsche Bank ↗
May 1, 14
■ Hold neutral · not a buy · 🎯$75
Price at call : $83.95 — gap to target -11%
Today : $500.77 — gap to target -85%
🎯 on CHE : no call matured yet · 📊 on Health : 53.8% · +9.7% (80 calls)
in progress (365j)
matures : May 1, 15
matures : May 1, 15
Deutsche Bank ↗
Oct 30, 13
■ Hold neutral · not a buy · 🎯$64
Price at call : $66.82 — gap to target -4%
Today : $500.77 — gap to target -87%
🎯 on CHE : no call matured yet · 📊 on Health : 53.8% · +9.7% (80 calls)
in progress (365j)
matures : Oct 30, 14
matures : Oct 30, 14
Deutsche Bank ↗
Sep 10, 13
■ Hold neutral · not a buy · 🎯$63
Price at call : $66.04 — gap to target -5%
Today : $500.77 — gap to target -87%
🎯 on CHE : no call matured yet · 📊 on Health : 53.8% · +9.7% (80 calls)
in progress (365j)
matures : Sep 10, 14
matures : Sep 10, 14
CL King
Jul 19, 13
■ Neutral neutral · not a buy
🎯 on CHE : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jul 19, 14
matures : Jul 19, 14
Oppenheimer ↗
Jun 11, 13
▲ Outperform · 🎯$85
Price at call : $72 — upside +18%
Today : $500.77 — upside -83%
Expected +18% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+25.1%
stock +25% · XLV +25%
matured Jun 11, 14
Oppenheimer ↗
Oct 3, 12
▲ Outperform · 🎯$80
Price at call : $70.09 — upside +14%
Today : $500.77 — upside -84%
Expected +14% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+2.6%
stock +3% · XLV +24%
matured Oct 3, 13
Frequently asked questions
Should I buy Chemed Corp. stock?
This isn't buy advice. For Chemed Corp., the analyst consensus is "Buy", with an average price target of $569 (+14% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 75% of the time (12 calls tracked on Chemed Corp.). We show the numbers — you decide.
Is it too late to buy Chemed Corp.? How high can it go?
The most bullish analyst target on Chemed Corp. is $650 (+30% above today's price); the average is $569. That's the upside they see. Check how reliable those analysts have actually been on Chemed Corp. on our site before trusting it.
Is Chemed Corp. still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 3 analysts have a real record on Chemed Corp., the best hitting 75% over 12 calls. Current consensus: "Buy". Make your call on data, not noise.
What has Chemed Corp.'s past performance been?
Historical returns and a "how much if I had invested" calculator: CHE performance & returns.
Does Chemed Corp. pay a dividend?
Yield, consistency and growth history of the dividend: CHE's dividend.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX